
usd may pm et
summari develop proprietari product use cardiologist physician heart surgeon
angioplasti heart surgeri procedur
price-to-earnings oper ep
mostli uncontest pioneer minim
devic support heart function particularli blood
pump compani typic maintain littl
debt howev compani lack product divers
pose risk especi devic becom obsolet
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
fy expect sale fall
million neg impact
impella use elect case full year sale
could surpris upsid patient volum
recov quickli recent physician train
outreach effort payoff sooner
long run see plenti runway
growth domest abroad earli
estim penetr
current address market
includ annual protect
right-sid heart failur patient
see germani japan key near-term
growth target wide accept
abmd product two countri
like lead product adopt surround
region earli estim
annual german market patient
penetr japanes market
penetr
addit posit view april
acquisit breeth develop
oxygen ecmo system
requir approxim abmd
believ trade fair
valu especi investor physician
confid shook confus fda
warn letter earli high
public studi novemb loos
associ impella devic outcom
wors exist standard care
neither event affect opinion
effect impella devic
support sizabl bodi evid howev
neg percept nonetheless hurt
sale respons event
began take substanti action increas
educ physician proper impella use
establish stronger relationship key
posit posit free cash flow think
firm troubl fund
oper forese futur enabl
compani return strong growth
risk price recommend includ
slower-than-expect return growth
unforeseen competit overestim end
market weaker-than-expect adopt
target base
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead provid temporari mechan circulatori support
devic develop manufactur market proprietari product design enabl
heart rest heal recov improv blood flow coronari arteri organ and/or
temporarili perform pump function heart compani product use cardiac
catheter lab cath lab intervent cardiologist electrophysiolog lab hybrid
lab heart surgeri suit heart surgeon physician might use devic patient
need hemodynam support angioplasti heart surgeri procedur
primari product impella product portfolio includ impella impella cp impella
rp impella ld impella product pipelin includ impella impella ecp impella
btr product servic revenu near futur impella devic
work expand usag awar impella product
one recent fda-approv product impella rp heart pump indic
provid temporari right ventricular support day certain patient develop acut right
heart failur decompens follow left ventricular assist devic implant myocardi infarct
heart transplant open-heart surgeri impella rp heart pump percutan temporari
ventricular support devic fda-approv safe effect acut right heart failur
market profil accord aha heart diseas stroke statist updat report
coronari heart diseas account approxim death
condit coronari arteri caus reduc blood flow insuffici oxygen deliveri
affect portion heart lead acut myocardi infarct ami commonli known heart
attack may lead heart failur condit heart unabl pump enough blood
bodi major organ
competit among provid treatment fail heart intens subject rapid
technolog chang evolv industri requir standard present futur
product could render obsolet uneconom result technolog advanc one
present futur competitor therapi includ drug therapi must
continu develop commerci new product technolog remain competit
cardiovascular medic technolog industri believ compet primarili basi
clinic superior support extens data innov featur enhanc patient benefit
product perform eas use reliabl
heart replac devic research effort canada europ japan
addit sever compani includ
terumo heart geting maquet cardiovascular sever
early-stag compani develop heart assist product includ implant left ventricular
assist devic miniatur rotari ventricular assist devic directli indirectli compet
major develop novemb share drop approxim valu
one day studi conclud impella use associ higher rate advers event
cost result run contrari plethora studi data demonstr improv patient
outcom impella usag base limit studi believ investor overreact
exampl studi control differ patient health patient treat impella
older health complic averag possibl explain studi conclus
nonetheless impella adopt uptak could hurt news appropri
manag situat
februari fda sent letter health care provid regard increas mortal risk
patient receiv abmd impella rp product fda later clarifi may lower surviv
rate impella rp specif patient consid salvag patient patient
standard therapi fail unfortun health care provid media outlet
wrong interpret initi fda letter product recal hurt earli sale divert
manag attent also subsequ clarifi shortli februari fda letter
increas mortal rate specif salvag patient recoveri right protocol patient
financi trend revenu grew fy fy reflect
five-year compound annual growth rate compound-annual-growth-rate -- one highest growth rate medic
equip suppli industri five-year ep compound-annual-growth-rate even higher ep fy
vs fy fy histor debt cash flow
grow free cash flow defin cash flow oper less capit expenditur grew
fy fy fy think financi sound
posit like remain way forese futur
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
confound rule analyz time period hospit
level patient level impella use associ higher rate advers
event cost result appear posit think
analysi requir understand recent data fit
plethora data demonstr improv patient outcom impella
usag base initi review studi appear studi
control patient health believ issu effect
impella pump could drive result studi exampl impella
devic may use frequent sickest patient could
impella associ higher mortal rate /kevin huang cfa
pm et cfra keep strong buy opinion share inc
keep target base
ep estim sep-q ep vs consensu
expect rais ep
share surg today low expect head quarter sep-q
revenu increas yoy million revenu grew
million intern revenu increas million
oper margin improv mar-q
prior-year quarter announc introduc recent approv
impella limit basi meanwhil continu
success launch smartassist platform although strateg
action invest global commerci team may provid immedi
benefit continu think make right move establish
impella product global standard care certain type compromis
analyst research note compani news
pm et cfra reiter buy opinion share inc
lift target base dcf model
mar-q ep vs estim lower
ep estim commenc ep estim
impella patient declin
mid-march april period compar prior-year period howev
expect quick recoveri patient volum delay care like result
greater need circulatori support light made
substanti effort increas remot capabl product
train view posit near term prioriti
preserv cash full-tim job continu invest innov
yesterday april announc acquisit breeth
develop oxygen ecmo system requir approxim
abmd patient breeth product call
ecpella pend fda approv /kevin huang cfa
pm et cfra reduc opinion share inc buy
strong buy continu view strongli
under-valued think like disrupt abmd recent
effort improv adopt impella devic initi
increas public real-world evid boost physician
confid impella devic exampl paus fda stemi-dtu
trial result disrupt believ
investor interest could remain mute near futur
take longer return revenu growth rate given
compani net cash posit posit free cash flow think
troubl fund oper forese futur
et cfra maintain strong buy opinion share inc
lower target price base
discount cash flow model dec-q ep vs surpass
consensu expect due slower-than-expect recoveri
sale lower fy ep estim fy
ep think compani take right
action assur physician impella benefit still
difficult determin return top-lin growth
nonetheless believ avail data support long-term use
impella product heart recoveri support encourag hear
conduct anoth random clinic trial call protect iv
develop eight month support class guidelin
recommend impella high-risk pci percutan coronari
intervent class guidelin would move impella statu
should-be-consid recommend high-risk pci /kevin huang cfa
et cfra keep strong buy opinion share inc
share fell precipit today announc
disappoint preliminari fiscal dec result guid fy
march revenu expect million million
particularli surpris news neg impact two
present novemb believ base mislead analys
announc take addit action educ stakehold
benefit impella devic increas public
real-world evid creat dedic faculti educ train
initi road show boost physician confid impella devic
continu posit view abmd financi posit substanti
long-term growth opportun await addit inform
schedul present morgan healthcar confer later today
pm et cfra maintain strong buy opinion share inc
share declin precipit today data
present american heart associ aha scientif session think
investor overreact studi conclud although unmeasur
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
